Abstracts tagged "SF-36 and axSpA"

Abstract Number: 1545 • ACR/ARP Annual Meeting 2019

Ixekizumab Significantly Improves Self-reported Overall Health as Measured by Short-Form-36 in Patients with Active Non-radiographic Axial Spondyloarthritis: 16- and 52-Week Results of a Phase 3 Randomized Trial (COAST-X)

Jessica Walsh¹, Marina Magrey ², Uta Kiltz ³, Xenofon Baraliakos ⁴, Maggie Weng ⁵, Theresa Hunter ⁶, Xiaoqi Li ⁶, Luis Leon ⁷, David Sandoval ⁷ and Kentaro Inui ⁸, ¹Division of Rheumatology, University of Utah, Salt Lake City, UT, ²Division of Rheumatology, The MetroHealth System and School of Medicine, Case Western Reserve University, Cleveland, OH, ³Rheumazentrum Ruhrgebiet/Ruhr University Bochum, Herne, Germany, Herne, Germany, ⁴Rheumazentrum Ruhrgebiet-Ruhr-University Bochum, Herne, Germany, Herne, Germany, ⁵National Cheng-Kung University Medical Center, Tainan, Taiwan (Republic of China), ⁶Eli Lilly and Company, Indianapolis, ⁷Eli Lilly and Company, Indianapolis, IN, ⁸Department of Orthopaedic Surgery, Osaka City University Graduate School of Medicine, Osaka, Japan